Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography

The FDA approved drug aprepitant is an antagonist of the Neurokinin 1 receptor (NK1R). Here the authors present aprepitant bound NK1R crystal structures and use NMR spectroscopy to gain further insights into the dynamics of aprepitant binding, which is of interest for further drug development.

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuanghong Chen, Mengjie Lu, Dongsheng Liu, Lingyun Yang, Cuiying Yi, Limin Ma, Hui Zhang, Qing Liu, Thomas M. Frimurer, Ming-Wei Wang, Thue W. Schwartz, Raymond C. Stevens, Beili Wu, Kurt Wüthrich, Qiang Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/1fea1939297743138267a644666827c0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1fea1939297743138267a644666827c0
record_format	dspace
spelling	oai:doaj.org-article:1fea1939297743138267a644666827c02021-12-02T16:57:42ZHuman substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography10.1038/s41467-019-08568-52041-1723https://doaj.org/article/1fea1939297743138267a644666827c02019-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-08568-5https://doaj.org/toc/2041-1723The FDA approved drug aprepitant is an antagonist of the Neurokinin 1 receptor (NK1R). Here the authors present aprepitant bound NK1R crystal structures and use NMR spectroscopy to gain further insights into the dynamics of aprepitant binding, which is of interest for further drug development.Shuanghong ChenMengjie LuDongsheng LiuLingyun YangCuiying YiLimin MaHui ZhangQing LiuThomas M. FrimurerMing-Wei WangThue W. SchwartzRaymond C. StevensBeili WuKurt WüthrichQiang ZhaoNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-8 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Shuanghong Chen Mengjie Lu Dongsheng Liu Lingyun Yang Cuiying Yi Limin Ma Hui Zhang Qing Liu Thomas M. Frimurer Ming-Wei Wang Thue W. Schwartz Raymond C. Stevens Beili Wu Kurt Wüthrich Qiang Zhao Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
description	The FDA approved drug aprepitant is an antagonist of the Neurokinin 1 receptor (NK1R). Here the authors present aprepitant bound NK1R crystal structures and use NMR spectroscopy to gain further insights into the dynamics of aprepitant binding, which is of interest for further drug development.
format	article
author	Shuanghong Chen Mengjie Lu Dongsheng Liu Lingyun Yang Cuiying Yi Limin Ma Hui Zhang Qing Liu Thomas M. Frimurer Ming-Wei Wang Thue W. Schwartz Raymond C. Stevens Beili Wu Kurt Wüthrich Qiang Zhao
author_facet	Shuanghong Chen Mengjie Lu Dongsheng Liu Lingyun Yang Cuiying Yi Limin Ma Hui Zhang Qing Liu Thomas M. Frimurer Ming-Wei Wang Thue W. Schwartz Raymond C. Stevens Beili Wu Kurt Wüthrich Qiang Zhao
author_sort	Shuanghong Chen
title	Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_short	Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_full	Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_fullStr	Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_full_unstemmed	Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_sort	human substance p receptor binding mode of the antagonist drug aprepitant by nmr and crystallography
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/1fea1939297743138267a644666827c0
work_keys_str_mv	AT shuanghongchen humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT mengjielu humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT dongshengliu humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT lingyunyang humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT cuiyingyi humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT liminma humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT huizhang humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT qingliu humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT thomasmfrimurer humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT mingweiwang humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT thuewschwartz humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT raymondcstevens humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT beiliwu humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT kurtwuthrich humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography AT qiangzhao humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
_version_	1718382490039615488

Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography

Ejemplares similares